Medicare plans to widen coverage of Alzheimer’s drugs that could win full approval as soon as this summer
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law.
For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.Biogen and Eisai’s Leqembi is up for full approval this summerZack Wittman for The Wall Street JournalDow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Richmond man sentenced for $1.4 million Medicare home health fraud schemeThe home health company owner allegedly billed Medicare for services not medically necessary or provided for several years. He's set to spend nearly five years behind bars.
Read more »
Arizona Opinion: Congress must protect Social Security and Medicare'If the United States defaults on its debts, its credit rating would plummet, and borrowing costs would skyrocket.'
Read more »
Medicare to expand coverage for a new class of costly Alzheimer’s drugsMedicare officials announced plans to broadly cover a new class of Alzheimer’s drugs following an intense lobbying campaign by patient advocates and drugmakers pressing for access to the first medications shown to slow cognitive decline from the disease.
Read more »
John Stossel: Social Security and Medicare are unsustainable time bombsOur politicians don’t have the guts to do anything about it. Or even talk about it.
Read more »
'This Isn't the End': McCarthy Takes Aim at Social Security, Medicare After Debt Ceiling Deal'MAGA Republicans want to reach into our pockets and steal our earned Social Security and Medicare benefits,' responded one advocacy group.
Read more »
Medicare unveils plan for coverage of new Alzheimer’s drugsPatient registry could be a barrier to coverage of new treatments, critics say.
Read more »